All In Biotech

Drug Trial Radar · NCT05607563

A Study of PM1009 (Anti-TIGIT/PVRIG) in Patients With Advanced Tumours

A Phase I Study to Evaluate the Tolerability, Safety, Pharmacokinetic Characteristics and Preliminary Efficacy of PM1009 (Anti-TIGIT/PVRIG) in Patients With Advanced Tumors

Last checked: Nov 20, 2026Latest source record: Feb 8, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

54

Planned (sponsor's estimate)

Start

Nov 21, 2022

Primary completion

Nov 2023

Study completion Dec 2023

Sponsor

Lead sponsor
Biotheus Inc.Industry
Sponsor type
Industry
First posted
Nov 7, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is being conducted to evaluate safety, tolerability, pharmacokinetics and preliminary efficacy of PM1009 for patients with advanced tumors, also to explore the recommended Phase Ⅱ Dose(RP2D) of PM1009. PM1009 is a new novel fully human anti-TIGIT x PVRIG bispecific antibody, containing a wildtype IgG1 Fc and has high monovalent affinity to each target, it can binds to both TIGIT and PVRIG overexpressing target cells and binds to TIGIT and PVRIG simultaneously.

Conditions

  • Advanced Tumor

Interventions

  • PM1009 injectionDrug

    Participants receive PM1009 intravenously, every 2 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Limited Toxicity(DLT)Time frame: up to 21 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Orient Hospital

    Shanghai, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.